Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Clinical trial NCT02282345 · COMPLETED

Trial details

NCT number: NCT02282345
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Adenocarcinoma Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation HER2/Neu Negative Invasive Breast Carcinoma

Start date: 2015-04-16
Primary completion: 2018-04-26
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.